complementation with chromosomes 2 and 3, respectively, were obtained from Drs CR Boland, M Koi and TA Kunkel. Complementation with chromosome 3 provides a wild-type copy of hMLH1 that renders the HCT116+ch3 cells MMR-proficient (Koi et al, 1994) . The hMSH2-deficient human endometrial carcinoma cell line HEC59 and its subline HEC59+ch2 (clone HEC59/2-4), complemented with chromosome 2, were also provided by Drs CR Boland, M Koi and TA Kunkel. In the HEC59+ch2 cells, the chromosome 2 complementation restores wild-type hMSH2 and MMR function (Umar et al, 1997) . The cells were grown as previously described . The status of expression of hMLH1 and hMSH2 was confirmed by Western blot. Cisplatin was obtained from Sigma (St Louis, MO, USA) and dissolved in 0.9% (w/v) saline. Lipofectin was purchased from Life Technologies (Gaithersburg, MD, USA).
Cellular pharmacology
The effect of MMR on the repair of cisplatin-damaged DNA was compared using two pairs of cell lines. The HCT116-derived sublines differed with respect to MMR activity due to the loss of hMLH1 function, and the HEC59 cells due to the loss of hMSH2 function. The HCT116 cells contain a hemizygous mutation in hMLH1 resulting in a truncated, non-functional protein (Boyer et al, 1995; Carethers et al, 1996) . Thus far, complementation of hMLH1 and hMSH2 defects by expression of these genes from a vector has not been reported by any laboratory; however, successful complementation has been achieved using whole chromosomes. The HCT116+ch3 subline is MMR-proficient due to complementation with a wild-type copy of hMLH1 on chromosome 3; the HCT116+ch2 subline is complemented with chromosome 2 and is MMR-deficient (Koi et al, 1994; Carethers et al, 1996) . Similarly, the HEC59 cells are mutated at different loci on both alleles of hMSH2 and are deficient in MMR activity (Boyer et al, 1995) ; the HEC59+ch2 subline complemented with a wildtype copy of hMSH2 on chromosome 2 is MMR-proficient (Umar et al, 1997) . The MMR-deficient HCT116 cells are 2.1-fold resistant to cisplatin when compared to the MMR-proficient HCT116+ch3 cells in clonogenic assays, and the MMR-deficient HEC59 cells are 1.8-fold more resistant to cisplatin than the MMR-proficient HEC59+ch2 cells . The complemented cells grown in G418 have remained stable for more than 2 years in culture, and repeat clonogenic assays confirmed these differences in cisplatin sensitivity (data not shown).
Assay of platinum adducts in DNA
The extent of DNA platination was measured by exposing exponentially growing cells for 1 h to 100 µM cisplatin; the cells were then washed with cold phosphate-buffered saline (PBS) and lysed in a buffer containing 1% sodium dodecyl sulphate (SDS), 2.6 M sodium chloride, 0.3 M EDTA pH 8.0. DNA was isolated by phenol-chloroform extraction and dissolved in buffer containing 10 mM Tris and 1 mM EDTA pH 8.0. Aliquots of the DNA were digested in 1 M hydrochloric acid at 75°C for 2 h and the hydrolysate was used for the quantitation of platinum (Pt) by flameless atomic absorption spectrophotometry (Perkin-Elmer Model 2380). The rate of cisplatin adduct removal was measured in cells that were exposed for 1 h to 40 and 80 µM cisplatin and harvested 0, 6, 20 and 28 h after the end of exposure. The Pt content of the DNA was measured by atomic absorption spectroscopy as described above.
Plasmid reactivation assay
A plasmid carrying a 2.4 kb fragment from pB/LUC that included the 1.6-kb firefly luciferase cDNA was prepared by ligating a SalI/NotI fragment that contained the luciferase coding region into the 6.9-kb mammalian expression vector pKEX-2-XR (Rittner et al, 1991) placing the luciferase expression under control of the cytomegalovirus (CMV) promoter. One to 4 mg of plasmid DNA was dissolved in buffer containing 10 mM Tris and 1 mM EDTA pH 7.4 and incubated with 5 µM cisplatin at 37°C for 3 h. The platinated DNA was then purified by ethanol precipitation and unreacted drug was removed by passage of the DNA through a G50 Sephadex column. This procedure resulted in plasmid DNA that was > 90% supercoiled as verified by gel electrophoresis. The platination procedure yielded 1.5 ± 1.4 pg µg -1 DNA which is equivalent to 9.3 adducts per plasmid or 3.2 adducts per Luc coding region and promoter. Similar levels of platination have previously been shown not to affect the efficiency of transfection (Eastman and Schulte, 1988) .
Equal number of cells (i.e. 200 000 per well) were transfected in serum-free medium with 1 µg platinated or unplatinated pKEX-2-XR-Luc in combination with 5 µl lipofectin for a period of 5 h. Intra-assay variability was minimized by using one lipofectin mixture for all samples in each experiment. Subsequently, the DNA was washed off and fresh medium was added. At various time points after transfection, triplicate samples were washed with ice-cold PBS and then lysed in a solution containing 1% Triton 12.0 ± 3.5 12.1 ± 3.6 10.5 ± 2.7 13.1 ± 2.7 12.2 ± 2.1 11.3 ± 3.3 20 6.4 ± 2.8 4.3 ± 1.7 5.3 ± 1.8 7.2 ± 3.0 6.8 ± 2.2 6.6 ± 2.0 28
1.1 ± 0.3 1.2 ± 0.2 0.9 ± 0.3 1.6 ± 0.5 1.8 ± 0.7 1.7 ± 1.3
The rates of platinum removal were determined in HCT116 sublines at 0, 6, 20 and 28 h after the end of 1 h exposure to 40 and 80 µM cisplatin. Initial adduct levels were the same in all HCT116 sublines, i.e. 384 fmol µg -1 DNA and 650 fmol µg -1 DNA following exposure to 40 µM and 80 µM cisplatin respectively. Values represent mean ± s.d. (n = 3) per cent of the initial content at the end of the 1 h treatment with cisplatin. There was no significant difference between MMR-proficient and -deficient cells in the rate of platinum removal over time.
X-100, 15 mM MgSO 4 , 4 mM EGTA, 1 mM dithiothreitol, and 25 mM glycylglycine at pH 7.8 for 10 min. After centrifugation for 5 minutes at 16 000 g, aliquots of the cleared lysate were assayed for luciferase activity as previously described (Brasier et al, 1989) . The generation of luciferase activity as a function of time was compared for cells transfected with the unplatinated versus platinated vector (Eastman and Schulte, 1988) . To control for variation in transfection efficiency between experiments, luciferase activity was expressed as percent of maximum activity attained in each experiment. In each cell line, the area under the curve of luciferase activity versus time was computed up to the time of maximal activity which was 36 and 20 h for HCT116 and HEC59 cells respectively. The efficiency of plasmid reactivation was calculated as the ratio of the area under the curve of the platinated vector to the area under the curve of the unplatinated plasmid.
RESULTS

Effect of MMR on platinum adduct formation and removal
We have previously shown that after a 1 h incubation in 100 µM cisplatin the HCT116+ch2 and HCT116+ch3 cells do not differ significantly in their total cellular uptake of Pt with accumulation being 303 ± 58 (s.d.) fmol µg -1 protein and 289 ± 82 (s.d.) fmol µg -1 protein in the two cell lines respectively (P = 0.75, two-tailed t-test, n = 4) . Thus, resistance to cisplatin in the HCT116+ch2 cells is not due to reduced drug uptake. Likewise, the extent of DNA platination was similar in the two cell lines . In order to determine whether loss of MMR altered the kinetics of adduct removal from the whole genome, the Pt removal rates were measured in the HCT116 cell lines at 0, 6, 20 and 28 h after the end of a 1 h exposure to 40 and 80 µM cisplatin. As shown in Table 1 , HCT116 cells and their chromosome-complemented sublines demonstrated a rapid decrease in adduct content over the first 6 h following exposure to both cisplatin concentrations, and the kinetics were similar to those previously reported for cisplatin adduct removal (Dijt et al, 1988; Eastman and Schulte, 1988; Jones et al, 1991) . However, there was no significant difference between MMR-proficient and -deficient cells in the rate of platinum removal over time.
Effect of MMR on plasmid reactivation
The effect of loss of MMR on the function of a gene inactivated by cisplatin adducts was examined by comparing the ability of MMRproficient and -deficient cells to express luciferase from a platinated plasmid-transfected into the cell. Figure 1 shows that luciferase activity appeared in both the MMR-proficient and -deficient HCT116 sublines with the same kinetics when they were transfected with non-platinated vector. Maximum luciferase activity was reached at 36 and 20 h in HCT116 and HEC59 cells, respectively. When the platinated vector was transfected into the MMR-deficient HCT116+ch2 subline, there was little impairment in the generation of luciferase activity ( Figure 1A) . However, when the same platinated vector was transfected into the MMRproficient HCT116+ch3 subline, both the rate of appearance of the luciferase activity and the maximal activity attained over the whole observation period were reduced ( Figure 1B) . A similar pattern was observed in the HEC59 system (Figure 2 ). The kinetics of appearance of luciferase activity was the same in the HEC59 and HEC59+ch2 cells in the absence of vector platination. However, the MMR-proficient HEC59+ch2 cells were less capable of generating luciferase activity from the platinated vector than the MMR-deficient HEC59 cells. Figure 3 shows that the efficiency of reactivation, calculated from all three sets of experiments as the ratio of the area under the curve of luciferase activity versus time for the platinated plasmid divided by that for the unplatinated plasmid in each cell line, was consistently lower in the MMR-proficient cells than in their MMR-deficient counterparts in both cell systems. The MMRproficient HCT116+ch3 cells were 2.1 ± 0.7-fold (± s.d., n = 3) less efficient at expressing luciferase from the platinated vector than their MMR-deficient HCT116+ch2 counterparts (P = 0.0355 by paired t-test for the comparison of MMR-proficient vs -deficient HCT116 cells). In the HEC59 system, the MMR-proficient HEC59+ch2 cells were 1.9 ± 0.6-fold (± s.d, n = 3) less efficient at expressing luciferase activity compared to MMRdeficient HEC59 cells (P = 0.002 by paired t-test for the comparison of MMR-proficient vs-deficient HEC59 cells).
DISCUSSION
The mechanism by which loss of MMR causes resistance to cisplatin is unknown. A current hypothesis is that MMR proteins serve as a detector for DNA damage caused by cisplatin, as they do for damage produced by methylating agents or the incorporation of 6-thioguanine, and that MMR proteins are involved in the generation of a pro-apoptotic signal since loss of MMR in cancer cells results in increased resistance to cisplatin (Branch et al, 1993; Kat et al, 1993; Aebi et al, 1996; Drummond et al, 1996; Fink et al, 1996) . It is, however, not known whether simple assembly of part or all of the MMR protein complex on the platinated DNA is sufficient to generate such a signal or whether the apoptosis is activated by additional damage done to the DNA resulting from attempts made by the MMR system to remove the cisplatin adduct. A futile cycle of excision and resynthesis has been suggested as the basis for the cytotoxicity of agents such as MNNG and 6-thioguanine that produce damage recognized by the MMR system (Karran and Bignami, 1994) .
Impaired cellular accumulation of cisplatin is a common mechanism of resistance in the majority of cell lines selected for resistance to this drug (Gately and Howell, 1993) . However, MMR-deficient HCT116+ch2 and -proficient HCT116+ch3 cells accumulated the same amount of Pt and had the same extent of DNA platination after a 1 h exposure to cisplatin. The fact that the nucleotide excision repair system proteins can both recognize and remove cisplatin adducts begs the question of whether the MMR system is similarly able to remove cisplatin adducts as well as to detect them. The observation that the kinetics of cisplatin adduct removal appeared to be equivalent in the MMR-proficient and -deficient HCT116 cells suggests that this is not the case. Thus, the difference in sensitivity to cisplatin cannot be explained by differential drug uptake or differential cytosolic detoxification of cisplatin prior to its reaction with the DNA, and the mechanism of resistance does not alter the rate of adduct removal from the total genome. One cannot conclude, however, that the MMR system plays no role in the actual removal of cisplatin adducts from the DNA since it has been established that cisplatin adducts are preferentially removed from transcribed genes as compared to the total genome, and that the coding strand is repaired preferentially compared to the non-coding strand (Jones et al, 1991; May et al, 1993) . Thus, measurement of total genomic platination may miss important functional differences in the ability of MMR-deficient and -proficient cells to successfully express genes damaged by platination, since assays of total genomic platination do not measure the final completion of the repair process. The reporter gene reactivation assay has several advantages over total genome Pt measurement as an assay of overall repair. First, generation of luciferase activity reflects repair activity directed to a transcribed gene. Second, the assay measures the ability of the repair systems to complete all steps in the process and actually generate a functional protein. Third, the reporter gene reactivation assay has previously been validated for cisplatin adduct repair (Sheibani et al, 1989; Jennerwein et al, 1991; Parker et al, 1991; Ali-Osman et al, 1994) . One limitation of this assay system is that it reflects repair processes occurring in an extrachromosomal segment of DNA rather than in an endogenous gene.
The finding that MMR proficiency resulted in impaired expression of luciferase from the platinated vector was unexpected. The fact that the same result was obtained in two independent cell types, each rendered MMR-deficient by the loss of a different MMR protein, lends credence to the observation. Several explanations are possible. First, successful binding of the MMR complex of proteins to the cisplatin adduct may sterically hinder the ability of nucleotide excision repair proteins to access and process the lesion, as has previously been suggested (Mello et al, 1996) . The ability of the nucleotide excision repair system to remove cisplatin adducts has been well-documented, as has the fact that adduct removal by this system is a major determinant of cellular sensitivity to cisplatin (reviewed in Zamble and Lippard, 1995) . Thus, steric hindrance by the MMR proteins would be expected to slow repair by the nucleotide excision repair system and reduce generation of luciferase activity. Such a mechanism has been proposed to explain the ability of another group of cisplatin adduct-binding proteins, the HMG proteins, to interfere with adduct repair (Huang et al, 1994) . However, in a recent study, (Mu et al, 1997) reported that addition of the hMSH2/hMSH6 heterodimer to a cell-free excision repair system did not impair the ability of the nucleotide excision repair system to remove cisplatin adducts from DNA. The assay system utilized by these investigators measured only the excision nuclease activity in the absence of transcription, and the possibility of a negative interaction between the MMR and nucleotide excision repair systems in assays including transcription needs further investigation.
A second possibility is that, following recognition, the MMR system processes the adduct in some way that impairs transcription, perhaps by damaging the template strand as has been suggested for the 6-thioguanine and MNNG adducts (Karran and Bignami, 1994) . The MMR system may incise the strand opposite the adduct resulting, through the action of an exonuclease, in the creation of a gap whose filling is blocked by the persistence of the adduct. Under circumstances where the gapped strand is the template strand this would be expected to diminish transcription.
Finally, a third possible explanation is that the MMR proteins normally prevent RNA polymerase II from bypassing the cisplatin adduct, and that when the MMR system is disabled there is a higher probability of successful bypass transcription. Transcriptional bypass of Pt adducts by RNA polymerase II in a similar reporter plasmid has previously been described, albeit at low levels for cisplatin (Mello et al, 1995) . Interestingly, the cisplatin-resistant human ovarian carcinoma cells A2780/CP70 have increased DNA replication bypass of cisplatin adducts compared to the parental A2780 cells (Vaisman et al, 1997) , and they have previously been reported to lack hMLH1 expression and MMR function . Additionally, the A2780/CP70 cells exhibit increased ability to reactivate a reporter gene . Further, defects in hMSH6 are associated with increased resistance and enhanced replicative bypass of cisplatin (Vaisman et al, 1998) . These findings suggest that the hMutSα heterodimer consisting of hMSH2 and hMSH6 participates in the recognition of cisplatin adducts and that the loss of hMutSα results in resistance to cisplatin by allowing enhanced replicative bypass of cisplatin adducts. Although transcriptional bypass is likely to generate mutant transcripts, a significant fraction of these may carry silent mutations that still permit the synthesis of functional proteins. Thus, successful transcription of damaged genes could explain the reduced toxicity of cisplatin adducts in cells lacking MMR.
Independent of the mechanism, it is of interest that the loss of MMR activity has an effect of similar magnitude on both the efficiency of luciferase expression and the level of cellular resistance to cisplatin. This is consistent with the hypothesis that the enhanced reactivation ability observed in the MMR-deficient cells is mechanistically linked to determinants of cellular resistance.
